ReviewFrontiers in cardiovascular medicine2026
Pharmacological mechanisms and clinical evidence of vasopressin, steroids, and epinephrine triple therapy in in-hospital cardiac arrest.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In-hospital cardiac arrest carries a hospital discharge survival rate of 22.6% in high-income settings, a figure unchanged over the past decade. Epinephrine reliably promotes return of spontaneous circulation (ROSC) but does not consistently improve neurologically intact survival. This limitation motivated the development of the vasopressin, steroids, and epinephrine (VSE) combination. This review examines the pharmacological rationale underpinning VSE and evaluates the clinical evidence across randomised trials, individual participant data analyses, and network meta-analyses. Vasopressin contributes V1a receptor-mediated vasoconstriction independent of adrenergic receptor status. Intra-arrest methylprednisolone enhances vascular reactivity and attenuates post-ROSC vasopressor requirements. Post-resuscitation hydrocortisone targets critical illness-related corticosteroid insufficiency, constituting a two-phase steroid strategy that defines the full Mentzelopoulos protocol. Pooled analysis of three randomised trials enrolling 869 patients assigns moderate certainty to the ROSC benefit and low certainty to survival and neurological outcome endpoints. A network meta-analysis of 36 trials enrolling 21,768 patients ranked VSE above all comparators for haemodynamic outcomes while leaving neurological endpoints unresolved. Individual patient data reanalysis identifies an independent protective effect of the corticosteroid component against post-resuscitation septic shock. The dissociation between ROSC and neurological recovery reflects insufficient statistical power for hard endpoints, protocol differences between trials, compartmentalised neuroinflammation only partially accessible to circulating glucocorticoids, and epinephrine-mediated cerebral microcirculatory impairment. The 2025 American Heart Association, European Resuscitation Council, and International Liaison Committee on Resuscitation guidelines do not recommend routine VSE during in-hospital cardiac arrest. Adequately powered trial evidence on patient-centred outcomes remains pending. Patient phenotype stratification and factorial trial design represent the most promising directions for future investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.